Vibegron CAS 1190389-15-1

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1190389-15-1

Name

Vibegron

Syn­onyms

(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]-2-pyrrolidinyl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidin-6-carboxamid [Ger­man] [ACD/IUPAC Name]
(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]-2-pyrrolidinyl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide [ACD/IUPAC Name]
(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phényl)méthyl]-2-pyrrolidinyl}méthyl)phényl]-4-oxo-4,6,7,8-tétrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide [French] [ACD/IUPAC Name]
1190389-15-1 [RN]
Pyrrolo[1,2-a]pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-, (6S)- [ACD/​Index Name]
Vibegron [USAN]
KRP-114V
MFCD28502057

SMILES

c1ccc(cc1)[C@H]([C@H]2CC[C@H](N2)Cc3ccc(cc3)NC(=O)[C@@H]4CCc5n4c(=O)ccn5)O

Std­InChI

InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1

Std­InChIKey

DJXRIQM­CROIR­CZ-XOEO­­CAA­JSA-N

Mol­e­c­u­lar Formula

C26H28N4O3

Mol­e­c­u­lar Weight

444.53

Prop­er­ties

Safe­ty Data

WGK Germany

3

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Iden­ti­fi­ca­tion Methods

HNMR, HPLC

Known Appli­ca­tion

Vibegron is a med­ica­tion pri­mar­i­ly used for the treat­ment of over­ac­tive blad­der (OAB) and symp­toms of uri­nary fre­quen­cy and urgency. Over­ac­tive blad­der is a com­mon uro­log­i­cal con­di­tion char­ac­ter­ized by fre­quent and uncon­trolled con­trac­tions of the blad­der, lead­ing to symp­toms such as uri­nary fre­quen­cy, urgency, and uri­nary incontinence.

Vibegron belongs to a class of drugs known as β3-adren­er­g­ic recep­tor ago­nists. It works by stim­u­lat­ing the β3-adren­er­g­ic recep­tors in the blad­der wall, caus­ing relax­ation of the blad­der smooth mus­cle, increas­ing blad­der capac­i­ty, and reduc­ing the fre­quen­cy and inten­si­ty of blad­der con­trac­tions. This action helps alle­vi­ate the symp­toms of over­ac­tive blad­der, improv­ing the qual­i­ty of life for patients.

It should be not­ed that Vibegron may cause some adverse reac­tions, includ­ing headache, nau­sea, diar­rhea, high blood pres­sure and uri­nary tract infec­tion. Before use, you should con­sult your doc­tor and learn more about the risks and con­traindi­ca­tions of the drug.

Vibegron is typ­i­cal­ly pre­scribed by health­care pro­fes­sion­als based on the indi­vid­ual patient’s con­di­tion and symp­toms. The dosage and admin­is­tra­tion should be adjust­ed accord­ing to the

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (https://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.